loading

About BILM

At BILM, we believe in the power of education, accreditation and excellence in longevity medicine for doctors in the UK.

Doctor reading a medical journal on a laptop in a hospital library

Contact Info

Illustration of lipoprotein(a) particles inside an artery wall with an ECG trace

The British Institute for Longevity Medicine (BILM) has reviewed the results of Lp(a)HORIZON, presented at the AHA Scientific Sessions 2026 and published in the New England Journal of Medicine. It is the first cardiovascular outcomes trial of a drug that specifically lowers lipoprotein(a).

What the trial found

The trial randomised 8,322 adults aged 18 to 80 with established cardiovascular disease and Lp(a) of at least 70 mg/dL (median 236 nmol/L) to monthly pelacarsen 80 mg or placebo. At 12 months, pelacarsen had lowered Lp(a) by 77.7 percentage points more than placebo. Yet over a median of 4.7 years, major adverse cardiovascular events were no lower: 12.3% versus 12.1% (HR 1.02, 95% CI 0.90–1.15). Each component (cardiovascular death, myocardial infarction, stroke and urgent revascularisation) was neutral, as was all-cause death (HR 0.98). The picture did not change in patients with Lp(a) of at least 90 mg/dL, or across the prespecified secondary analyses. The study chair described the result as neutral, not a near miss.

What it does not tell us

Lp(a)HORIZON tested one drug, an antisense oligonucleotide, and only in secondary prevention. It tells us nothing about primary prevention. That is where longevity medicine works: lowering lifetime risk before a first event. Small interfering RNA (siRNA) drugs lower Lp(a) further, by about 94–95% for lepodisiran in phase 2, and they are given far less often. Their outcome trials have finished enrolling and are now underway. ACCLAIM-Lp(a) (lepodisiran) includes high-risk people who have not yet had an event, and OCEAN(a)-Outcomes is testing olpasiran.

BILM’s position

  1. Raised Lp(a) remains a well-established, largely inherited risk factor, and BILM supports including it in baseline cardiovascular risk assessment.
  2. Elevated Lp(a) should prompt earlier and more intensive control of all modifiable risk, especially apoB/LDL cholesterol and blood pressure, in line with current guidance.
  3. There is currently no evidence that drugs which specifically lower Lp(a) reduce cardiovascular events. Until outcome data show benefit, they should be used only within clinical trials.
  4. One neutral trial does not close the question. BILM urges sponsors and investigators running or planning Lp(a) outcome trials, particularly in primary prevention, to continue and report them in full, whatever the result. Their data are just as important to patients and to the science of healthy ageing.

Sources

Prev post